Skip to Main Content

Paper Details

Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study.
Eur J Cancer
6
2022
Author NameAffiliation
Niven MehraRadboud University Medical Center
Craig Gedye
Fred SaadCentre Hospitalier de L'Universite de Montreal
Michael A CarducciHopkins Kimmel Cancer Center
  • 1 - 4

Datasets

Release 1.2